EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study

Tianyue Zhai iD, Takashi Mitamura iD, Lei Wang, Shimpei I Kubota, Masaaki Murakami, Shinya Tanaka, Hidemichi Watari

Cancer Medicine · 2023

DOI: 10.1002/cam4.5674 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Tianyue Zhai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Hokkaido University Faculty of Medicine, Hokkaido University, Hokkaido, Sapporo, Japan. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Carcinoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Kobayashi International Scholarship Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti‐angiogenic therapy with bevacizumab (BEV), an anti‐VEGF antibody, plays a critical role in the treatment of ovarian cancer. However, despite an encouraging initial response, most tumors become resistant to BEV over time, and a new strategy that enables sustainable treatment using BEV is therefore needed.

Methods

To overcome the resistance to BEV in patients with ovarian cancer, we performed a validation study of combination therapy with BEV (10 mg/kg) and the CCR2 inhibitor BMS CCR2 22 (20 mg/kg) (BEV/CCR2i) using 3 consecutive patient‐derived xenografts (PDXs) of immunodeficient mice.

Results

BEV/CCR2i demonstrated a significant effect of growth suppression in the BEV‐resistant serous PDX and BEV‐sensitive serous PDX compared with BEV (30.4% after the second cycle and 15.5% after the first cycle, respectively), and treatment cessation did not attenuate this effect. Tissue clearing and immunohistochemistry with an anti‐α‐SMA antibody suggested that BEV/CCR2i suppressed angiogenesis from the host mice more than BEV. In addition, human CD31 immunohistochemistry revealed that BEV/CCR2i decreased microvessels originating from the patients to a significantly greater degree than BEV. Regarding the BEV‐resistant clear cell PDX, the effect of BEV/CCR2i was unclear during the first five cycles, but the following two cycles of increased‐dose BEV/CCR2i (CCR2i 40 mg/kg) significantly suppressed tumor growth compared with BEV (28.3%) by inhibiting the CCR2B‐MAPK pathway.

Conclusions

BEV/CCR2i showed a sustained anticancer immunity‐independent effect in human ovarian cancer that was more significant in serous carcinoma than in clear cell carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsCarcinomaHumansAnimalsMiceFemaleBevacizumabDrug Resistance, NeoplasmDisease Models, AnimalReceptors, CCR2

Stichwörter der Autor:innen

CCR2 inhibitorangiogenesisantiangiogenic drugbevacizumabpreclinical drug evaluation

Substanzen

BevacizumabCCR2 protein, humanReceptors, CCR2Ccr2 protein, mouse

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Hokkaido University Faculty of Medicine, Hokkaido University, Hokkaido, Sapporo, Japan.
  • Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Hokkaido, Sapporo, Japan.
  • Department of Cancer Pathology, Hokkaido University Faculty of Medicine, Hokkaido University, Hokkaido, Sapporo, Japan.
  • Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Hokkaido, Sapporo, Japan.
  • Group of Quantum immunology, Institute for Quantum Life Science, National Institute for Quantum and Radiological Science and Technology (QST), Chiba, Japan.
  • Division of Molecular Neuroimmunology, Department of Homeostatic Regulation, National Institute for Physiological Sciences, National Institutes of Natural Sciences, Okazaki, Japan.

ORCID-Profile: Tianyue Zhai, Takashi Mitamura

Förderung

  • Japan Society for the Promotion of Science
  • Kobayashi International Scholarship Foundation

Zitieren

APA

Zhai, T., Mitamura, T., Wang, L., Kubota, S. I., Murakami, M., Tanaka, S., & Watari, H. (2023). Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study. Cancer Medicine. https://doi.org/10.1002/cam4.5674

Vancouver

Zhai T, Mitamura T, Wang L, Kubota SI, Murakami M, Tanaka S, et al. Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study. Cancer Medicine. 2023. doi:10.1002/cam4.5674

BibTeX
@article{Zhai2023,
  author = {Zhai, Tianyue and Mitamura, Takashi and Wang, Lei and Kubota, Shimpei I and Murakami, Masaaki and Tanaka, Shinya and Watari, Hidemichi},
  title = {Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.5674}
}
Kostenlos starten →